Home / 2021 / June / 17

Daily Archives: June 17, 2021

HOKA ONE ONE Names FCB First-Ever Global Creative AOR

New partnership marks next expansion chapter in company’s incredible success story



SAN FRANCISCO, June 17, 2021 (GLOBE NEWSWIRE) — HOKA ONE ONE®, a division of Deckers Brands (NYSE: DECK), has announced the appointment of FCB as its first-ever global creative agency of record following a competitive review. FCB WEST, the network’s nimble creative boutique in San Francisco, will serve as the global lead office and will tap into FCB’s network of offices around the world.

Founded in 2009, HOKA is one of the fastest-growing performance footwear and apparel brands, committed to innovation and design to create positive change. The appointment of FCB signals the next expansion chapter in HOKA’s incredible growth story that saw a 62% year-over-year sales growth through the pandemic.

“As we set our sights on $1B and beyond, it’s the right time to hire HOKA’s first strategic AOR. With a brand as special as HOKA, it was important that we find the right partner who takes the responsibility of brand stewardship to heart. FCB demonstrated a curiosity, passion and deep understanding of HOKA that won us over.” – Wendy Yang, President, Performance Lifestyle Group – HOKA ONE ONE & Teva, Decker Brands

“With the power of FCB behind us, our focus will be on amplifying the uniqueness of HOKA to new and existing consumers. We’ve always been a very high-touch brand, connecting with consumers and adding value along their journey. Now we will extend our reach even further using a digitally driven approach because we know that once a consumer experiences our brand and products, they become fans for life.” – Norma Delaney, Vice President of Global Brand Marketing, HOKA ONE ONE

FCB will begin working with HOKA and its other agency partners immediately and expects the brand’s first global campaign under this new partnership to debut in 2022.

“HOKA is an incredible brand on a thrilling growth trajectory. People that know HOKA are passionate about it in a way that is rare. We’re excited to create work that is as bold, convention-defying and iconic as the shoes themselves.” – Simon White, President & CSO, FCB West

HOKA ONE ONE® is one of the fastest-growing performance footwear and apparel brands in history. Conceived in the mountains, HOKA footwear delivers an unprecedented combination of enhanced cushioning and support for a uniquely smooth ride. Every day, HOKA pushes the innovation and design of its footwear and apparel by teaming up with a deep roster of world champions, taste makers and everyday athletes. From finish lines to everyday life, HOKA fans love the brand for its bold and unexpected approach, and its belief in the power of humanity to create change for a better world. HOKA empowers a world of athletes to fly over the earth. For more information, visit hokaoneone.com or follow @hokaoneone. #TimeToFly

FCB (Foote, Cone & Belding) is a global, award-winning and integrated marketing communications company with a heritage of creativity and success dating from 1873. Named Adweek’s 2020 Global Agency of the Year, Cannes Lions 2019 North American Creative Agency of the Year and a 2019 Ad Age A-List global top 10, FCB focuses on creating Never Finished campaign ideas that have the power to transform brands, businesses and communities. With more than 8,000 people in 109 operations in 80 countries, the company is part of the Interpublic Group of Companies (NYSE: IPG) and is the agency partner behind some of the world’s most admired global brands including Levi’s, Clorox, Anheuser-Busch InBev, GE, BMW and more. Visit fcb.com or follow @FCBglobal on Instagram and Twitter and FCB Global on Facebook and LinkedIn.

Titus Wouda Kuipers
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7110b3a2-7138-46ad-b55f-2a70e2089193


Firefly Games teams up with Riva Technology and Entertainment to release a brand new L.O.L Surprise!™ mobile game in a licensing agreement with MGA Entertainment

LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) — Firefly Games Inc. announced today that they have partnered with MGA Entertainment to launch a global L.O.L Surprise!™ Room Makeover mobile game coming this summer on all iOS and Android devices. This partnership was established through the multiple brand licensing deal between MGA Entertainment and Riva Technology and Entertainment (RTE) that was announced recently. Beloved fans of L.O.L Surprise!™ will now be able to experience their favorite toy in a fresh new way with L.O.L Surprise!™ Room Makeover.

L.O.L Surprise!™ Room Makeover boasts a unique blend of Match-3 gameplay with the ability to decorate different themed rooms as well as incorporating the brand’s iconic trademark of unboxing L.O.L Surprise!™ Balls, and more! The Firefly team is already in the works of planning post-launch features and new content to further captivate existing fans.

“We have been working on some great Hollywood movie IPs over the years, now we see an expansion opportunity to diversify and leverage our current strengths into toy brands,” said Michael Zhang, CEO of Firefly Games. “MGA is a great partner to work with and we are hoping to add additional value to the brand and the players. It also could be a good chance for us to build our own metaverse with this IP.”

“Digital games are an important way to build community and ensure that our fans feel connected to the L.O.L Surprise!™ lifestyle,” says Isaac Larian, CEO & Founder of MGA.

The company is seeking to publish L.O.L Surprise! Room Makeover globally on July 1, 2021.

About Firefly Games 
Firefly Games, founded in 2015, is a mobile game publisher and developer for the global iOS and Android market. The Firefly team are not only experts in the mobile gaming space, but they have immense experience working with major studios and brands for world-renowned intellectual properties (IP) from Skydance Media, Dreamworks Animation, NBC Universal, and now MGA Entertainment on creating the perfect games for beloved IP.

About MGA Entertainment 
MGA Entertainment, Inc., a consumer entertainment products company headquartered in Chatsworth, California creates innovative proprietary and licensed products including toys and games, dolls, consumer electronics, home décor, stationery and sporting goods. The MGA family includes award winning brands such as L.O.L. Surprise!™Little Tikes®, Bratz®, LaLaLoopsy™, Secret Crush™Tobi™ Robot SmartwatchRainbow High™Poopsie Slime Surprise!™Sing-a-Long Lilly and AmiRescue Tales™VIRO Rides™Na! Na! Na! Surprise™ and Zapf Creation®. Visit us at www.mgae.com.

About Riva Technology and Entertainment:
Founded in 2002, with a global presence stretching from the USA to East Asia, RTE has successfully been delivering the vision of tomorrow for close to 20 years. RTE’s group of companies hold an industry advantage in their ability to take every project from concept to execution, all housed under one roof. The complementary companies cover location-based entertainment, brand and Intellectual Property licensing, content development, consumer products, gaming, and esports.

Michael Zhang
[email protected]

Amanda Gazali
[email protected]


Align Technology Honors 10 Million Invisalign Smiles Milestone With US$1 Million to Operation Smile for Children Born With Cleft Lip And Cleft Palate

  • In recognition of its 10 million Invisalign smiles milestone, Align donated $10 million to the Align Foundation donor-advised fund, which has now funded US$1 million to Operation Smile
  • Previously announced campaign “10 Million Smiles. 10 Million Thanks” centers on the transformative power of Invisalign treatment through the eyes of Invisalign patients
  • Align hopes to inspire others to share their smiles with the world using #10MInvisalignSmiles

TEMPE, Ariz., June 17, 2021 (GLOBE NEWSWIRE) — Align Technology, Inc. (“Align”) (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, today announced that the Align Foundation, the Company’s donor-advised fund through Fidelity Charitable, has donated US$1 million to Operation Smile, a global surgical nonprofit, to help children around the world born with cleft conditions receive safe, effective, and timely cleft surgery and comprehensive care.

“Operation Smile’s mission strongly resonates with Align’s purpose of transforming smiles and changing lives,” said Raj Pudipeddi, chief innovation, product and marketing officer and senior vice president, Align Technology. “We are proud to support a future where more smiles can be transformed through safe surgery and medical treatment – and hope to inspire others through our donation to help Operation Smile change the lives of more children.”

The “10 Million Smiles. 10 Million Thanks” campaign is based on the transformative power of Invisalign treatment as seen through the eyes of Invisalign patients. The donation to Operation Smile builds on that goal and aims to help more children around the world to smile by raising awareness and generating support and funding for Operation Smile. Operation Smile provides surgery and ongoing care for people affected by cleft lip and cleft palate in resource-limited environments.

“We are so appreciative of the dedication and support from Align Technology over the years and are excited for what we can do to bring families renewed hope, and help children around the world smile even more as a result of this latest donation,” said Kristie Magee Porcaro, chief strategy officer, Operation Smile. “Together, we’re improving the health of many children and ensuring that they have the opportunity for a better future.”

Align Technology initiated a wave of photo sharing activity by asking its followers on social media channels around the world to share their smiles and to help change a child’s life using #10MInvisalignSmiles. The Company is working with Operation Smile and Invisalign ambassadors and regional stakeholders to encourage their communities of followers to join with them in the awareness campaign. Tag yourself using #10MInvisalignSmiles and help Align increase awareness of Operation Smile and its global mission. To learn more, please visit: www.10MInvisalignSmiles.com

For information about Operation Smile, please visit http://www.operationsmile.org

About Operation Smile
Operation Smile revolutionized cleft surgery globally in 1982. With nearly four decades of experience as one of the largest surgical volunteer-based nonprofits, Operation Smile staff, its private-public partnerships and thousands of volunteers have improved the health and dignity of patients with cleft conditions, helping them to better breathe, eat, speak and live lives of greater quality and confidence. While one cleft surgery can bring immediate transformation to a child’s life in as little as 45 minutes, Operation Smile is committed to providing patients with health that lasts—being there to offer patients additional surgeries, dentistry, psychological services, speech therapy and other essential cleft treatments. Its training and education programs elevate local surgical standards and entire health systems to aid safe surgery and strengthen a global network to reach more people earlier in their lives. You can learn more about its transformative and healing work by visiting www.operationsmile.org or by following @operationsmile on social media.

The Align Foundation
Launched in 2020, the Align Foundation provides a structured means by which significant donations are directed from a donor-advised fund overseen by Fidelity Charitable, with the flexibility to provide smaller monetary donations, processes to donate our products, as well as an organized way to involve our employees in giving activities. In March 2020, we funded $1 million to support COVID-19 relief efforts globally and donated personal protective equipment (PPE) such as N95 masks and worked with partners to source supplies for additional PPE to help hospitals and healthcare providers. To date, Align has contributed over $4.6 million to charitable causes including Operation Smile, America’s Toothfairy, and other non-profits dedicated to youth development through schools and educational programs. Over the last two years, our employees have volunteered over 10,000 hours as part of our dedicated month of giving in October called Month of Smiles.

About Align Technology, Inc.
Align Technology designs, manufactures and offers the Invisalign system, the most advanced clear aligner system in the world, iTero intraoral scanners and services, and exocad CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 200 thousand doctor customers and is key to accessing Align’s 500 million consumer market opportunity worldwide. Align has helped doctors treat over 10.2 million patients with the Invisalign system and is driving the evolution in digital dentistry through the Align Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit www.aligntech.com for more information.

For additional information about the Invisalign system or to find an Invisalign doctor in your area, please visit www.invisalign.com. For additional information about iTero digital scanning system, please visit www.itero.com. For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit http://www.exocad.com.

Align Investor Relations Zeno Group
Madelyn Homick Sarah Johnson
(408) 470-1180 (828) 551-4201
[email protected] [email protected]

Constellation Brands Invests in Aaron Paul & Bryan Cranston’s Artesanal ‘Dos Hombres’ Mezcal

VICTOR, N.Y., June 17, 2021 (GLOBE NEWSWIRE) — Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it has acquired a minority stake in Dos Hombres, an artesanal and hand-crafted mezcal brand created by Breaking Bad co-stars Aaron Paul and Bryan Cranston. The investment was made through Constellation’s venture capital group, and Dos Hombres remains independently owned and will continue to manage, market, and produce its award-winning mezcals.

“Aaron and Bryan have turned their shared passion for mezcal into a truly unique brand and have created an exceptional liquid that receives frequent praise from both the industry and its consumers,” said Jennifer Evans, vice president, Constellation Ventures. “Our goal is to make strategic, minority investments in high potential brands in growing categories, and the U.S. mezcal market continues to show great potential. We’re excited to further invest in the category with a great team and brand that we feel has a lot of growth runway.”

The U.S. mezcal market has grown rapidly in the last few years and is expected to continue its strong growth trajectory. The overall U.S. mezcal category grew 14% in 2020 according to IWSR, and ultra-premium mezcal (priced above $30 per bottle) is projected to be the largest and fastest-growing segment within the category.

After forming what the duo dubs a “special bond” while filming the critically acclaimed AMC television show and knowing they would not be sharing the screen together for quite some time, Paul and Cranston began discussing ways they could work together again as they sipped cocktails at a bar in New York. They soon found inspiration from the drinks in their hands and set their sights on teaming up to create a truly special mezcal.

“We have fallen in love with all things mezcal – the process, the community behind the spirit, the tradition,” said Paul. “We were just two guys on a quest to find a spirit that we felt everyone would love, and we’ve put a lot of energy into this. We couldn’t be more excited for the next chapter with Constellation and continuing to build this brand. We have big hopes and dreams for Dos Hombres and we are thrilled that Constellation’s vision for Dos Hombres is aligned with ours.”

Launched in 2019, Dos Hombres is the product of multiple generations of proud mezcal producers from the small village of San Luis del Rio, in a remote section of Oaxaca, Mexico. The brand is made with hand-selected Espadín agave that are cooked in underground pit ovens, milled by donkey-drawn tahona, fermented for 7-10 days with mountain spring water, and double distilled in copper stills. The end product is a well-balanced mezcal that features signature smokiness, yet smooth with hints of apple, mango, local Oaxacan fruits, and wood.

“It really has been an incredible journey,” added Cranston. “From an idea at a bar, to searching all over Oaxaca, hiking through the most majestic landscape in search of a mezcal that spoke to us, to meeting incredible people along the way, to where we are today – we can’t wait to keep sharing this brand with the world.”

Terms of the agreement were not disclosed.


At Constellation Brands (NYSE: STZ and STZ.B), our mission is to build brands that people love because we believe sharing a toast, unwinding after a day, celebrating milestones, and helping people connect, are Worth Reaching For. It’s worth our dedication, hard work, and the bold calculated risks we take to deliver more for our consumers, trade partners, shareholders, and communities in which we live and work. It’s what has made us one of the fastest-growing large CPG companies in the U.S. at retail, and it drives our pursuit to deliver what’s next.

Today, we are a leading international producer and marketer of beer, wine, and spirits with operations in the U.S., Mexico, New Zealand, and Italy. Every day, people reach for our high-end, iconic imported beer brands such as Corona Extra, Corona Light, Corona Premier, Modelo Especial, Modelo Negra, and Pacifico, and our high-quality premium wine and spirits brands, including the Robert Mondavi brand family, Kim Crawford, Meiomi, The Prisoner brand family, SVEDKA Vodka, Casa Noble Tequila, and High West Whiskey.

But we won’t stop here. Our visionary leadership team and passionate employees from barrel room to boardroom are reaching for the next level, to explore the boundaries of the beverage alcohol industry and beyond. Join us in discovering what’s Worth Reaching For.

To learn more, follow us on Twitter @cbrands and visit www.cbrands.com.

Mike McGrew 773-251-4934 / [email protected]
Amy Martin 585-678-7141 / [email protected]
Patty Yahn-Urlaub 585-678-7483 / [email protected]
Marisa Pepelea 312-741-2316 / [email protected]

A downloadable PDF copy of this news release can be found here: http://ml.globenewswire.com/Resource/Download/d9225f12-2bd0-4541-b6d4-e9f43b1ca6ef


Rancho Santa Fe Bio, Inc. Enters into Worldwide Exclusive License Agreement with Sanofi for Ataciguat

SAN DIEGO and PARIS, June 17, 2021 (GLOBE NEWSWIRE) — Rancho Santa Fe Bio, Inc. (“RSF Bio” or the “Company”), a San Diego, California-based clinical-stage cardiovascular platform company, today announced that it has entered into an exclusive worldwide license agreement with Sanofi, a global biopharmaceutical company. This agreement provides RSF Bio with Sanofi’s rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue development of Ataciguat through clinical trials in the United States and potentially in select international countries.

Before signing this license agreement, RSF Bio entered into a worldwide exclusive license agreement in December 2019 with Mayo Clinic for the use of Ataciguat in the treatment of patients with calcific aortic valve stenosis (“CAVS”). Under that license, Mayo Clinic assigned to RSF Bio its US IND No. 119,829 along with additional patents, patent applications and know-how.

CAVS is a progressive disease that afflicts predominately the older populations with a prevalence of 2% in patients over the age of 55 years. Its prevalence increases with age to approximately 12% or higher in populations >75 years of age. (Osnabrugge et al., J Am Coll Cardiol. 2013 and Faggiano et al., Am J Cardiol. 2003). CAVS is characterized by hardening of the aortic leaflets, which progresses over years and is predominately due to a maladaptive process of calcium deposition in the valves. CAVS is often fatal within a few years from symptom onset, if untreated. Currently, no medical treatment has been proven to be effective, and the treatment of choice for severe disease is aortic valve replacement, either by surgical aortic valve replacement (“SAVR”) or transcatheter aortic valve replacement (“TAVR”). RSF Bio is currently in an advanced stage of development of a novel pharmaceutical treatment with the drug Ataciguat, building upon a Phase IIb clinical trial. RSF Bio is also in the early planning stages of studying application for Ataciguat in certain other uses and indications.

Sanofi originally investigated Ataciguat in numerous preclinical studies and conducted clinical trials with the drug involving over 1,000 patients in total for three different indications: (a) stable angina, (b) peripheral arterial disease and (c) neuropathic pain. Following a reprioritization of its research and development pipeline, Sanofi provided Ataciguat to the New Therapeutic Uses (“NTU”) program at the U.S. National Institutes of Health’s National Center for Advancing Translational Sciences Program (“NCATS”). This program is designed to encourage the application of repurposed drugs into other clinical trials. The laboratory of Jordan Miller, Ph.D., at Mayo Clinic focuses on mechanisms underlying the progression of calcium build-up in CAVS. He was awarded a grant through the NCATS program to conduct preclinical studies with Ataciguat in CAVS, followed by Phase I and Phase II clinical trials at Mayo Clinic.

“The NCATS New Therapeutic Uses program developed and disseminated innovative approaches to three-way collaborations between government, pharmaceutical companies and academic medical centers to accelerate treatment development,” said Christine Colvis, Ph.D., Director of Drug Development Partnership Programs at NCATS. “The negotiation process to set up collaborative research agreements is a bottleneck in the establishment of public-private partnerships. The NTU template legal agreements provided a strong launching point for the negotiations, speeding the process,” she added. “We are excited to see the goals of the program being realized through the successful progression of this project by RSF Bio to potentially Phase III clinical testing and the promise it holds to deliver better treatment options to patients suffering from CAVS.”

“We are pleased about the potential of Ataciguat and the benefit it may offer to people suffering from CAVS,” said Alban de La Sablière, Senior Vice President, Head of Sanofi Partnering.  “After a reprioritization of our portfolio, we made a decision to repurpose this asset with NCATS and Mayo Clinic for Phase I and Phase II clinical trials and now with RSF Bio in order to advance science and bring treatment options to patients with this unmet medical need.”

“This has been an exciting journey so far, from the support we received from NCATS, to our extensive interactions and close partnerships with Sanofi, and now continuing advancement of Ataciguat towards clinical use with RSF Bio,” says Dr. Jordan Miller, the Chair of the Scientific Advisory Board of RSF Bio. “I am confident that the RSF Bio team will continue the advancement of therapies for CAVS and investigating applications of Ataciguat in other indications.”

“We are excited about adding the Sanofi rights to those which we have already received from Mayo Clinic through its NCATS funding,” said Randy Berholtz, the Chair and Chief Executive Officer of RSF Bio. “We believe we now have all of the pieces necessary to move Ataciguat along to the next level of clinical trials in the United States and internationally. We are happy to work with Mayo Clinic Venture’s team and to have Dr. Miller as Chair of our Scientific Advisory Board. We look forward to collaborating with them and him on this effort involving Ataciguat in CAVS,” he continued.

About Ataciguat
Ataciguat is a novel anthranilic acid derivative that belongs to a structural class of sGC activators that can activate the oxidized form of sGC. Ataciguat has been developed through a collaboration involving Sanofi, NCATS and Mayo Clinic. Ataciguat has undergone extensive pre-clinical and clinical development including Phase I and Phase II clinical trials at Mayo Clinic for treatment of the progression of CAVS. The drug and its application in CAVS is now licensed to RSF Bio for further development through clinical trials and if successful, for future commercialization.

About Rancho Santa Fe Bio, Inc.
RSF Bio is a San Diego, California clinical stage cardiovascular platform company. RSF Bio has exclusively licensed from the Mayo Clinic and from Sanofi Ataciguat for the treatment of the progression of CAVS. RSF Bio is also involved in developing additional indications for Ataciguat, developing AVS biomarkers and in conducting research and development of additional small molecules drugs in the cardiovascular and other fields. RSF Bio’s website is www.rsfbio.com and for more information please contact the Company at [email protected].

General Fusion to build its Fusion Demonstration Plant in the UK, at the UKAEA Culham Campus

New partnership between General Fusion and UKAEA is a landmark collaboration in the development of fusion, a technology for the world’s low-carbon future

General Fusion’s Demonstration Plant

A look at General Fusion’s planned Fusion Demonstration Plant at the UKAEA Culham Campus.

VANCOUVER, Canada and LONDON, UK, June 17, 2021 (GLOBE NEWSWIRE) — (BST) — The UK Atomic Energy Authority (UKAEA) and General Fusion have announced an agreement under which General Fusion will build and operate its Fusion Demonstration Plant (FDP) at UKAEA’s Culham Campus. General Fusion will enter into a long-term lease with UKAEA following construction of a new facility at Culham to host the FDP. The FDP will demonstrate General Fusion’s proprietary Magnetized Target Fusion (MTF) technology, paving the way for the company’s subsequent commercial pilot plant. General Fusion will benefit from the cluster of fusion supply chain activities in the UK, centered on UKAEA’s globally recognized expertise and presence in the field.

Amanda Solloway, Science Minister for UK Government said: “This new plant by General Fusion is a huge boost for our plans to develop a fusion industry in the UK, and I’m thrilled that Culham will be home to such a cutting-edge and potentially transformative project. Fusion energy has great potential as a source of limitless, low-carbon energy, and today’s announcement is a clear vote of confidence in the region and the UK’s status as a global science superpower.”

The Fusion Demonstration Plant at Culham is the culmination of more than a decade of advances in General Fusion’s technology, and represents a major milestone on the company’s path to commercialization. The Fusion Demonstration Plant will verify that General Fusion’s MTF technology can create fusion conditions in a practical and cost-effective manner at power plant relevant scales, as well as refine the economics of fusion energy production, leading to the subsequent design of a commercial fusion pilot plant. Construction is anticipated to begin in 2022, with operations beginning approximately three years later.

General Fusion and UKAEA intend to collaborate on a range of fusion energy technologies for power plant design and operation.

“Coming to Culham gives us the opportunity to benefit from UKAEA’s expertise,” stated Christofer Mowry, CEO, General Fusion. “By locating at this campus, General Fusion expands our market presence beyond North America into Europe, broadening our global network of government, institutional, and industrial partners. This is incredibly exciting news for not only General Fusion, but also the global effort to develop practical fusion energy.”

The Culham Campus, the home of the UK’s national fusion research programme, is owned and managed by UKAEA, widely recognized as a world leader in fusion energy development and innovation.

“This is a great development for UKAEA, very much in line with our mission to lead the development of sustainable fusion energy, and builds on our long heritage of hosting major fusion facilities such as the Joint European Torus,” said Ian Chapman, CEO of UKAEA.

About General Fusion
General Fusion’s mission is to pursue the commercialization of fusion energy based on its proprietary Magnetized Target Fusion technology. The company is based in Vancouver, Canada, with locations in Washington, D.C., and London, U.K. The company was established in 2002 and is funded by a global syndicate of leading energy venture capital firms, industry leaders, and technology pioneers. General Fusion’s partnership with the UKAEA coincides with an expansion of the company’s global headquarters and research facilities in Vancouver, Canada, and a growing presence in the United States.

Twitter: @GeneralFusion         More information: www.generalfusion.com

Media contact:
Grace Peach
Director, Marketing and Communications
General Fusion
Email: [email protected]
Phone: 1-866-904-0995

About UK Atomic Energy Authority
The UK Atomic Energy Authority (UKAEA) carries out fusion energy research on behalf of the UK Government at Culham Science Centre near Oxford. UKAEA oversees Britain’s fusion programme, headed by the MAST Upgrade (Mega Amp Spherical Tokamak) experiment. It also hosts the world’s largest fusion research facility, JET (Joint European Torus), which it operates for European scientists under a contract with the European Commission.

Fusion research at Culham is funded by the Engineering & Physical Sciences Research Council (EPSRC) and by the European Union under the EURATOM treaty.

Twitter: @UKAEAofficial         More information: www.gov.uk/ukaea

Media contact:
Nick Holloway
UKAEA Media Manager
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/10dddd6f-2034-4cca-98b8-be66f10b601b

Synchronoss Announces CFO Transition Plan

Company Reaffirms Fiscal Year 2021 Guidance

BRIDGEWATER, N.J., June 16, 2021 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital products and platforms, today announced a CFO transition plan with current Chief Financial Officer (CFO) David Clark stepping down from his role on August 9, 2021, to pursue other personal and career interests. Clark’s transition is unrelated to the Company’s financial reporting and business performance, and the Company is reaffirming 2021 guidance previously provided on May 10, 2021, in parallel with today’s announcement. Clark was appointed CFO in August 2018.

Commenting on Clark’s departure, Jeff Miller, President and CEO of Synchronoss, said: “I’ve enjoyed working alongside David and thank him for his commitment to the Company. David joined Synchronoss to make enhancements to our operational controls and reporting. During his tenure he has helped Synchronoss navigate successfully through significant improvements in management of operating expenses and implementation of financial governance and controls. I firmly believe his contributions have positioned us for future growth and success. On a personal note, I wish him only the best with his future endeavors and appreciate his support during this leadership transition.”

An executive search for Clark’s replacement is currently underway. He will remain in his current role until his departure date and will support Synchronoss as it transitions the CFO role to a successor.

About Synchronoss
Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services and content they love. That’s why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync. Learn more at www.synchronoss.com

Forward-Looking Statements

This press release includes statements concerning Synchronoss and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “believes,” “potential” or “continue” or other similar expressions are intended to identify forward-looking statements. Synchronoss has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks relating to the Company’s ability to sustain or increase revenue from its larger customers and generate revenue from new customers, the Company’s expectations regarding expenses and revenue, the sufficiency of the Company’s cash resources, the Company’s growth strategies, the anticipated trends and challenges in the business and the market in which the Company operates, the Company’s expectations regarding federal, state and foreign regulatory requirements, the pending lawsuits against the Company described in its most recent SEC filings, and other risks and factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, which are on file with the SEC and available on the SEC’s website at www.sec.gov. The company does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Media Contacts

For Synchronoss:
Anais Merlin, CCgroup UK
Diane Rose, CCgroup US
E: [email protected]

Investor Contact
For Synchronoss: Todd Kehrli/Joo-Hun Kim, MKR Investor Relations, Inc., E: [email protected]